Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies

Siobhan M. Kehoe, Ned L. Williams, Rasheed Yakubu, Douglas A. Levine, Dennis S. Chi, Paul J. Sabbatini, Carol A. Aghajanian, Richard R. Barakat, Nadeem R. Abu-Rustum

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: To report the incidence of intestinal obstruction after intraperitoneal chemotherapy (IP) in women with ovarian, tubal, or peritoneal malignancies, and determine the frequency of malignant versus adhesion-related obstruction. Methods: Patients who were treated with at least one dose of IP chemotherapy between 1986 and 1997, and who had at least 3 month follow-up, were included. Data regarding admissions for gastrointestinal obstruction complaints, radiologic diagnosis of intestinal obstruction and medical or surgical management of obstruction were recorded. Results: We identified 334 patients; 307 met our inclusion criteria. A total of 104 (34%) patients developed symptomatic intestinal obstruction after IP therapy commenced. The overall incidence of adhesion-related or mechanical bowel obstruction was only 4%. In the group of patients with a mechanical bowel obstruction, the median time to diagnosis of obstruction was 21 months (range, 2-51) after initiation of IP treatment. Surgical intervention to relieve the obstruction was performed in 6 (50%) patients diagnosed with adhesion-related bowel obstruction. Similarly, in those diagnosed with a malignant bowel obstruction, 42 (48%) were taken to the operating room in an attempt to relieve the obstruction. Conclusion: Intestinal obstructions developed in a third of patients who received IP therapy as part of their treatment for advanced ovarian, tubal, or peritoneal cancer. However, the majority of the obstructions are related to progression of malignant intra-abdominal disease. Only 4% of the patients develop intestinal obstruction due to intestinal adhesions after IP treatment.

Original languageEnglish (US)
Pages (from-to)228-232
Number of pages5
JournalGynecologic Oncology
Volume113
Issue number2
DOIs
StatePublished - May 2009

Fingerprint

Intestinal Obstruction
Drug Therapy
Incidence
Neoplasms
Therapeutics
Operating Rooms

Keywords

  • Intestinal obstruction
  • Intraperitoneal chemotherapy
  • Ovarian tubal malignancies
  • Peritoneal malignancies

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. / Kehoe, Siobhan M.; Williams, Ned L.; Yakubu, Rasheed; Levine, Douglas A.; Chi, Dennis S.; Sabbatini, Paul J.; Aghajanian, Carol A.; Barakat, Richard R.; Abu-Rustum, Nadeem R.

In: Gynecologic Oncology, Vol. 113, No. 2, 05.2009, p. 228-232.

Research output: Contribution to journalArticle

Kehoe, SM, Williams, NL, Yakubu, R, Levine, DA, Chi, DS, Sabbatini, PJ, Aghajanian, CA, Barakat, RR & Abu-Rustum, NR 2009, 'Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies', Gynecologic Oncology, vol. 113, no. 2, pp. 228-232. https://doi.org/10.1016/j.ygyno.2009.01.016
Kehoe, Siobhan M. ; Williams, Ned L. ; Yakubu, Rasheed ; Levine, Douglas A. ; Chi, Dennis S. ; Sabbatini, Paul J. ; Aghajanian, Carol A. ; Barakat, Richard R. ; Abu-Rustum, Nadeem R. / Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. In: Gynecologic Oncology. 2009 ; Vol. 113, No. 2. pp. 228-232.
@article{306a96213f084739868a5331fbe949d1,
title = "Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies",
abstract = "Objectives: To report the incidence of intestinal obstruction after intraperitoneal chemotherapy (IP) in women with ovarian, tubal, or peritoneal malignancies, and determine the frequency of malignant versus adhesion-related obstruction. Methods: Patients who were treated with at least one dose of IP chemotherapy between 1986 and 1997, and who had at least 3 month follow-up, were included. Data regarding admissions for gastrointestinal obstruction complaints, radiologic diagnosis of intestinal obstruction and medical or surgical management of obstruction were recorded. Results: We identified 334 patients; 307 met our inclusion criteria. A total of 104 (34{\%}) patients developed symptomatic intestinal obstruction after IP therapy commenced. The overall incidence of adhesion-related or mechanical bowel obstruction was only 4{\%}. In the group of patients with a mechanical bowel obstruction, the median time to diagnosis of obstruction was 21 months (range, 2-51) after initiation of IP treatment. Surgical intervention to relieve the obstruction was performed in 6 (50{\%}) patients diagnosed with adhesion-related bowel obstruction. Similarly, in those diagnosed with a malignant bowel obstruction, 42 (48{\%}) were taken to the operating room in an attempt to relieve the obstruction. Conclusion: Intestinal obstructions developed in a third of patients who received IP therapy as part of their treatment for advanced ovarian, tubal, or peritoneal cancer. However, the majority of the obstructions are related to progression of malignant intra-abdominal disease. Only 4{\%} of the patients develop intestinal obstruction due to intestinal adhesions after IP treatment.",
keywords = "Intestinal obstruction, Intraperitoneal chemotherapy, Ovarian tubal malignancies, Peritoneal malignancies",
author = "Kehoe, {Siobhan M.} and Williams, {Ned L.} and Rasheed Yakubu and Levine, {Douglas A.} and Chi, {Dennis S.} and Sabbatini, {Paul J.} and Aghajanian, {Carol A.} and Barakat, {Richard R.} and Abu-Rustum, {Nadeem R.}",
year = "2009",
month = "5",
doi = "10.1016/j.ygyno.2009.01.016",
language = "English (US)",
volume = "113",
pages = "228--232",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies

AU - Kehoe, Siobhan M.

AU - Williams, Ned L.

AU - Yakubu, Rasheed

AU - Levine, Douglas A.

AU - Chi, Dennis S.

AU - Sabbatini, Paul J.

AU - Aghajanian, Carol A.

AU - Barakat, Richard R.

AU - Abu-Rustum, Nadeem R.

PY - 2009/5

Y1 - 2009/5

N2 - Objectives: To report the incidence of intestinal obstruction after intraperitoneal chemotherapy (IP) in women with ovarian, tubal, or peritoneal malignancies, and determine the frequency of malignant versus adhesion-related obstruction. Methods: Patients who were treated with at least one dose of IP chemotherapy between 1986 and 1997, and who had at least 3 month follow-up, were included. Data regarding admissions for gastrointestinal obstruction complaints, radiologic diagnosis of intestinal obstruction and medical or surgical management of obstruction were recorded. Results: We identified 334 patients; 307 met our inclusion criteria. A total of 104 (34%) patients developed symptomatic intestinal obstruction after IP therapy commenced. The overall incidence of adhesion-related or mechanical bowel obstruction was only 4%. In the group of patients with a mechanical bowel obstruction, the median time to diagnosis of obstruction was 21 months (range, 2-51) after initiation of IP treatment. Surgical intervention to relieve the obstruction was performed in 6 (50%) patients diagnosed with adhesion-related bowel obstruction. Similarly, in those diagnosed with a malignant bowel obstruction, 42 (48%) were taken to the operating room in an attempt to relieve the obstruction. Conclusion: Intestinal obstructions developed in a third of patients who received IP therapy as part of their treatment for advanced ovarian, tubal, or peritoneal cancer. However, the majority of the obstructions are related to progression of malignant intra-abdominal disease. Only 4% of the patients develop intestinal obstruction due to intestinal adhesions after IP treatment.

AB - Objectives: To report the incidence of intestinal obstruction after intraperitoneal chemotherapy (IP) in women with ovarian, tubal, or peritoneal malignancies, and determine the frequency of malignant versus adhesion-related obstruction. Methods: Patients who were treated with at least one dose of IP chemotherapy between 1986 and 1997, and who had at least 3 month follow-up, were included. Data regarding admissions for gastrointestinal obstruction complaints, radiologic diagnosis of intestinal obstruction and medical or surgical management of obstruction were recorded. Results: We identified 334 patients; 307 met our inclusion criteria. A total of 104 (34%) patients developed symptomatic intestinal obstruction after IP therapy commenced. The overall incidence of adhesion-related or mechanical bowel obstruction was only 4%. In the group of patients with a mechanical bowel obstruction, the median time to diagnosis of obstruction was 21 months (range, 2-51) after initiation of IP treatment. Surgical intervention to relieve the obstruction was performed in 6 (50%) patients diagnosed with adhesion-related bowel obstruction. Similarly, in those diagnosed with a malignant bowel obstruction, 42 (48%) were taken to the operating room in an attempt to relieve the obstruction. Conclusion: Intestinal obstructions developed in a third of patients who received IP therapy as part of their treatment for advanced ovarian, tubal, or peritoneal cancer. However, the majority of the obstructions are related to progression of malignant intra-abdominal disease. Only 4% of the patients develop intestinal obstruction due to intestinal adhesions after IP treatment.

KW - Intestinal obstruction

KW - Intraperitoneal chemotherapy

KW - Ovarian tubal malignancies

KW - Peritoneal malignancies

UR - http://www.scopus.com/inward/record.url?scp=63749092195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63749092195&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.01.016

DO - 10.1016/j.ygyno.2009.01.016

M3 - Article

VL - 113

SP - 228

EP - 232

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -